

Receipt date: 01/03/2007

Express Mail Label No.: EV886687095US

Date of Deposit: January 3, 2007

10567953 - GAU: 1654

Attorney Docket No. 24852-502 NATL

Page 1 of 2

Please type a plus sign (+) in this box



PTO/SB (12-97)

OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	10/567,953
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	International Application Number	PCT/US04/26161
	I.A. Filing Date	August 12, 2004
	Priority Date	August 29, 2003
	First Named Inventor	Bacopoulos
	Group Art Unit / Conf. No.:	Not Yet Assigned / 5497
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-502 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	5,369,108	11/29/04	Breslow, et al.	514	266	10/04/91
	A2	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00
	A3	6,811,788	11/02/04	Yu	424	278	01/17/01
	A4	2002/0044919	04/18/02	Yu	424	85.1	01/17/01
	A5	2003/0059812	03/27/03	Richon, et al.	435	6	06/14/02
	A6	2003/0096777	05/22/03	Besterman, et al.	514	44	05/14/02
	A7	2003/0114525	06/19/03	Kammer, et al.	514	557	05/20/02
	A8	2003/0144340	07/31/03	Long, et al.	514	422	09/26/02
	A9	2003/0235588	12/25/03	Richon, et al.	424	146.1	02/14/03
	A10	2004/0116407	06/17/04	Borisy, et al.	514	217	07/11/03

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
	B1	WO	2004/103358 A2, A3	Novartis AG/Novartis Pharma GmbH	December 2, 2004	X
	B2	WO	2005/023179 A2, A3	Aton Pharma, Inc./Sloan-Kettering	March 17, 2005	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Butler, et al. "The Histone Deacetylase Inhibitor SAHA Arrests Cancer Cell Growth, Up-Regulates Thioredoxin-Binding Protein-2, and Down-Regulates Thioredoxin"; <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 99, No. 18, pp. 11700-11705 (September 3, 2002).
	C2	Castro-Galache, et al. "Susceptibility of Multidrug Resistance Tumor Cells to Apoptosis Induction by Histone Deacetylase Inhibitors"; <i>Int. J. Cancer</i> , Vol. 104, pp. 579-586 (2003).
	C3	Henderson, et al. "Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)"; <i>The Journal of Biological Chemistry</i> , Vol. 278, No. 14, pp. 12579-12589 (April 4, 2003).
	C4	Kelly, et al. "Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously"; <i>Clinical Cancer Research</i> , Vol. 9, No. 10, pp. 3578-3588 (September 1, 2003).
	C5	Kim, et al. "Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA"; <i>Cancer Research</i> , Vol. 63, pp. 7291-7300 (November 1, 2003).
	C6	Peart, et al. "Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors"; <i>Cancer Research</i> , Vol. 63, pp. 4460-4471 (August 1, 2003).
	C7	Zhu, et al. "The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells"; <i>Curr. Med. Chem.-Anti-Cancer Agents</i> , Vol. 3, No. 3, pp. 187-199 (2003).
	C8	International Search Report for PCT/US04/26161 mailed April 6, 2005.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

Receipt date: 01/03/2007

Express Mail Label No.: EV886687095US

Date of Deposit: January 3, 2007

10567953 - GAU: 1654

Attorney Docket No. 24852-502 NATL

Page 2 of 2

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Andrew D. Kosar/	Date Considered	03/01/2010
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.